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3Abstract
Background: Trichotillomania is a functionally impairing, often overlooked disorder with no FDA-
approved medications indicated for its treatment. The ability of clinical trials to detect beneficial 
effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo 
response rate. Very little is known about baseline demographic and clinical characteristics that 
may be predictive of placebo response in such patients. 
Methods: 104 participants assigned to placebo were pooled from five double-blind trials
conducted at three sites in the United States and Canada. Participants were classified as placebo 
responders or non-responders based on a cut-off of 35% reduction in symptom severity on the 
Massachusetts General Hospital Hair Pulling Scale (MGH-HPS). Baseline group differences were 
characterized using t-tests and equivalent non-parametric tests as appropriate. 
Results: Thirty-one percent of individuals assigned to placebo treatment showed a significant 
clinical response to placebo.  Placebo responders (n=32) and non-responders (n=72) did not differ 
significantly on any demographic or clinical variable.
Discussion: Predictors of placebo response for trichotillomania remain elusive and do not appear 
similar to those reported for other mental health disorders. 
4Introduction
Trichotillomania (TTM) is a potentially disabling, under-recognized condition in which 
individuals repeatedly pull out their hair, leading to hair loss. Psychosocial problems are common 
among individuals with TTM and may include significantly reduced quality of life, lowered self-
esteem, and impaired social functioning (Diefenbach et al., 2005; Houghton et al., 2016; Grant 
and Chamberlain, 2016). Although trichotillomania has been described for almost two centuries, it
remains poorly understood with limited data regarding pathophysiology and treatment 
(Christenson & Mansueto, 1999; Chamberlain et al., 2009; Grant and Chamberlain, 2016). 
Most of the double-blind, placebo-controlled pharmacological studies of TTM have failed 
to separate symptomatic changes significantly from placebo. Interestingly, our clinical experience 
suggests that in many cases this lack of effectiveness seems less to do with the medication failing 
to produce results and more to do with the high placebo response rates. For example, in a double-
blind study of inositol, 37% of the placebo group (using a last observation carried forward 
approach; LOCF) responded (Leppink et al., 2016). Understanding the complexity of the placebo 
response in these disorders is challenging due to the limited sizes of the research samples (e.g., 
sample sizes of <25 taking placebo in any single study). The present study seeks to overcome this 
limitation by using a relatively large data set which combines participants from five double-blind, 
placebo controlled pharmacological trials in TTM conducted in the United States and Canada 
(Dougherty et al., 2006; Grant et al., 2009; Van Ameringen et al., 2010; Grant et al., 2014; 
Leppink et al., 2016).
Understanding the factors associated with a placebo response in TTM may allow for a
5more efficient examination of potentially beneficial pharmacological treatments for this disabling 
disorder. Here, we pooled data from studies in which all participants met diagnostic criteria for 
TTM, took placebo pills, and were seen regularly by a medical professional. Many factors have 
been suggested to contribute to high placebo response rates clinical trials in mental health. In the 
case of major depressive disorder, interpersonal interactions, the strength of the therapeutic 
alliance with research personnel (Leuchter et al., 2014), or lesser levels of depression severity 
(Khan et al., 2002; Khan et al., 2005) may result in a placebo response.  Data from trials of 
bipolar depression suggest that baseline illness severity and trial duration predict placebo response 
(Neirenberg et al., 2015). The case of obsessive compulsive disorder, however, has yielded no 
clear clinical variables associated with the placebo response (Mataix-Cols, et al., 1999). Based on 
the (admittedly limited) extant mental health literature and our clinical experience, we 
hypothesized that the placebo effect in TTM would be associated with milder illness severity at 
baseline.
Methods
Subjects
Data from participants in TTM treatment studies at the University of Chicago, University 
of Minnesota, McMaster University, and Massachusetts General Hospital (MGH)/Harvard 
Medical School who were assigned to placebo during the clinical trial were included in this study
(one exception was the sertraline trial which had a 2-week single-blind placebo phase prior to 
treatment assignment in the double-blind portion of the study and only 2 were randomized to 
placebo treatment in this study arm). All participants had a primary diagnosis of TTM based on 
6expert clinical assessment. As is customary in TTM research, prior to May 2013, the diagnosis 
was based on DSM-IV criteria with or without the endorsement of increasing and decreasing 
tension associated with pulling (criteria B and C). After the release of the DSM-5 in May 2013, all 
subjects met the DSM-5 criteria for TTM. Other inclusion criteria included age 18 or older, the 
ability to be interviewed in person, and able to provide written informed consent. Participants 
from MGH were excluded if they met criteria for a lifetime diagnosis of psychosis, autism, or 
mental retardation. Participants at the University of Chicago and the University of Minnesota 
were excluded if they were pregnant, met lifetime criteria for bipolar disorder or a psychotic 
disorder, or had an organic mental disorder.  Participants taking any psychotropic medications 
were included as long as the dose of medication had been stable for at least three months prior to 
study entry. Participants taking part at McMaster University were excluded if they had comorbid 
primary mental disorders; were less than moderately ill at baseline; had received olanzapine 
without success in the past; had comorbid OCD, depression, substance use disorder; or had a 
lifetime history of schizophrenia, bipolar disorder, dementia, or other neurologic disorders. 
All study procedures were carried out in accordance with the latest version of the 
Declaration of Helsinki. Study approvals were received from the Institutional Review Boards of 
all relevant institutions prior to study initiation. Detailed methodologies of the various clinical 
trials have been previously published (Dougherty et al., 2006; Grant et al., 2009; Van Ameringen 
et al., 2010; Grant et al., 2014; Leppink et al., 2016). Data were de-identified according to the 
Safe Harbor method for de-identification prior to data sharing (§164.514(b)) (U.S. Department of 
Health & Human Services, 2012). After all procedures were explained, all participants provided 
written informed consent.
7All participants in the trials completed a full psychiatric assessment using the Structured 
Clinical Interview for DSM-IV (SCID-I) (First et al. 1995). Subjects also completed general 
demographic questionnaires, and self-report and clinician-administered severity measures. In 
addition, each subject underwent a semi-structured interview to examine psychiatric disorders in 
first-degree relatives (except for the sertraline study). No relatives were interviewed directly.
Assessments
The Massachusetts General Hospital Hair Pulling Scale (MGH-HPS) (Keuthen et al., 
1995) was used to assess severity of TTM symptoms.: The MGH-HPS is a valid and reliable 
seven-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived 
control over behavior, and distress associated with hair pulling over the preceding seven days. 
Analysis of the MGH-HPS has demonstrated two separate factors with acceptable reliability for 
both: “severity” and “resistance and control” (Keuthen et al., 2007). 
Psychosocial functioning was assessed using the Sheehan Disability Scale (SDS) 
(Sheehan, 1983): The SDS is a valid and reliable, three-item, self-report scale that assesses 
psychosocial functioning in work, social or leisure activities, and home/family life. Scores on the 
scale range from 0 to 30 with higher scores indicating better perceived psychosocial functioning.
Depression and anxiety symptoms over the past month were assessed using clinician-
administered Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and Hamilton 
Anxiety Rating Scale (HAM-A; Hamilton, 1959), respectively. Scores on these two measures 
were not a basis for inclusion/exclusion.
8Data Analysis
Baseline characteristics of the placebo participants pooled from all of the studies were 
presented in terms of means and standard deviations for continuous variables and frequencies and 
percentages for categorical variables. 
Patients were grouped as placebo responders (>35% reduction in MGH-HPS total scores 
from baseline to end-point) or non-responders. The two groups were compared on pertinent 
demographic and clinical measures using independent sample t-tests or equivalent non-parametric 
tests as indicated in the text. This being an exploratory study, statistical significance was defined 
as p<0.05 uncorrected, one-tailed.
As a secondary analysis, we also pooled all data from the same studies from active 
treatment responders, and compared these data to those of placebo responders.
Results
Data from 104 participants with primary TTM (N=91 [87.5%] female, mean age 32.6 ±
11.0 years) who were assigned placebo were included in the analysis. In the pooled analysis, 
31.4% of participants assigned to placebo improved at least 35% on the MGH-HPS during 
placebo treatment. 
In terms of the individual studies, the sample sizes for those receiving placebo, and N [%] 
of subjects responding to placebo, were as follows: Inositol N=19, 7 [36.8%] were placebo 
responders; N-acetylcysteine (NAC) N=25, 6 [24.0%] were placebo responders; Naltrexone 
N=30, 9 [30.0%] were placebo responders; Olanzapine N=12, 3 [25.0%] were placebo 
responders; Sertraline N=18, 7 [39.9%] were placebo responders. The studies did not differ 
9significantly on placebo response rate (Likelihood Ratio = 1.619, df=4, p=0.805). 
Clinical variables of responders and non-responders are presented in Table 1, where it can 
be seen that the groups did not differ from each other in terms of demographic variables or clinical 
characteristics. Clinical variables of placebo responders are compared to reference data for active 
treatment responders in Table 2. Active treatment responders completed significantly more study 
weeks than placebo responders, and had marginally higher rate of OCD (although OCD was 
uncommon in both groups). 
Table 1. Clinical Variables of Participants with Trichotillomania Who Did and Did Not 
Respond to Placebo
Variables Those Who 
Responded to 
Placebo (n=32)
Those Who Did 
Not Respond to 
Placebo (n=72)
Statistical Test P 
value
Age, years 30.4 (10.9) 33.5 (11.0) t=1.314, df=1,102 0.192
Gender, female, N [%] 28 [87.5%] 63 [87.5%] LR=0.772, df=2 @ 0.680
Education level 3.6 (1.2) 3.6 (1.3) t=0.062, df=1,68 0.951
Race, white Caucasian, N [%] 20 [98.0%] 48 [98.0%] LR=0.691, df=1 0.406
Frequency of hair pulling
(mean number of minutes per 
day during the week prior to 
study entry)
66.6 (38.6) 87.7 (67.1) t=1.379, df=1,72 0.172
10
MGH-HPS total score at 
baseline
17.4 (3.4) 18.2 (4.6) t=0.881, df=1,102 0.380
Weeks of study completed 8.5 (3.6) 8.3 (3.9) t=-0.193, df =1,72 0.848
Previous treatment for 
trichotillomania, yes, N[%]
14 [63.6%] 29 [56.9%] LR = 0.294, df=1 0.588
First degree relative with 
grooming disorder, “yes” N[%]
3 [13.6%] 6 [11.5%] LR = 0.063, df=1 0.803
Sheehan Disability Scale 10.9 (6.7) 9.3 (6.3) t=0.928, df=1,102 0.357
HAM-A 4.2 (3.4) 4.7 (3.9) t=0.489, df=1,72 0.626
HAM-D 5.6 (5.9) 6.6 (6.9) t=0.633, df=1,102 0.509
Lifetime Psychiatric History
Mood Disorder
Anxiety Disorder
Alcohol Use Disorder
OCD
ADHD
14 [63.6%]
5 [22.7%]
1 [4.5%]
0 [0%]
1 [4.5%]
19 [36.5%]
9 [17.3%]
3 [5.8%]
2 [3.8%]
9 [17.3%]
LR = 0.0, df=1
LR = 0.288, df=1
LR = 0.047, df=1
LR=1.435, df=1
LR = 2.561, df=1
0.989
0.591
0.829
0.231
0.145
All values are mean (±SD) for continuous variables and N [%] for categorical variables. 
Abbreviations: LR = likelihood ratio test. @ = one individual in the non-placebo 
responders group identified as intersex. 
Table 2. Clinical Variables of Participants with Trichotillomania Who Were Placebo 
Responders Compared to Active Treatment Responders
11
Variables Those Who 
Responded to 
Placebo (n=32)
Those Who 
Responded to 
Active 
Treatment 
(n=52)
Statistical Test P 
value
Age, years 30.4 (10.9)
32.6 (11.1)
t=0.865, df=1,82 0.390
Gender, female, N [%] 28 [87.5%]
44 [84.6%]
LR=0.992, df=2 @ 0.601
Education level 3.6 (1.2)
3.8 (1.0) t=0.638, df=1,55 0.527
Race, white Caucasian, N [%] 20 [98.0%] 33 [94.3%] LR=1.851, df=1 0.396
Frequency of hair pulling
(mean number of minutes per 
day during the week prior to 
study entry)
66.6 (38.6) t=1.379, df=72 0.172
MGH-HPS total score at 
baseline
17.4 (3.4) 17.9 (4.1) t=0.619, df=1,82 0.538
Weeks of study completed 8.5 (3.6) 10.2 (2.2) t=2.073, df=1,56 0.047
Previous treatment for 
trichotillomania, yes, N[%]
14 [63.6%] 20 [55.6%] LR=0.370, df = 1 0.543
First degree relative with 
grooming disorder, “yes” N[%]
3 [13.6%] 6 [16.7%] LR = 0.097, df=1 0.755
Sheehan Disability Scale 10.9 (6.7) 11.4 (7.0) t=1.145, df=1,56 0.258
12
HAM-A 4.2 (3.4) 4.2 (0.5) t=0.044, df=1,56 0.965
HAM-D 5.6 (5.9) 6.0 (8.1) t=1.323, df=1,80 0.190
Lifetime Psychiatric History
Mood Disorder
Anxiety Disorder
Alcohol Use Disorder
OCD
ADHD
14 [63.6%]
5 [22.7%]
1 [4.5%]
0 [0%]
1 [4.5%]
16 [44.4]
9 [25.0%]
0 [0.0%]
4 [11.1%]
5 [13.9%]
LR=0.370, df=1
LR=0.039, df=1
LR=1.968, df=1
LR=3.995, df=1
LR=1.433 , df=1
0.543
0.844
0.161
0.046
0.231
All values are mean (±SD) for continuous variables and N [%] for categorical variables. 
Abbreviations: LR = likelihood ratio test. @  = one individual in the non-placebo 
responders group identified as intersex. 
Discussion
To our knowledge, this is the first study that has examined clinical variables associated 
with the placebo response in the pharmacological treatment of TTM. Given that the pooled 
placebo response in these studies was 31%, and that there is as of yet no FDA-approved 
medication indicated for the treatment of TTM, determining predictors of placebo response is
crucial for the timely and cost-effective development of pharmacological interventions.
Knowledge of variables associated with placebo response might also be useful for sample 
enrichment in clinical trials.  In addition, a placebo response rate of 31% suggests that larger 
numbers will be needed in future placebo controlled efficacy studies of TTM than have been 
previously considered necessary.
Some research suggests that the placebo effect in clinical drug trials generally may 
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influence as many as 49% of treated patients, that the effect may be related to symptom severity, 
and that its duration may vary from minutes to years (Breidert & Hofbauer, 2009). Interestingly, 
the placebo response rate in our sample is much higher than previously found in OCD treatment 
trials, a disorder with possible biological links to TTM (<20%; Greist et al., 1995; Stein et al., 
1995; Pigott & Seay, 1999; Ackerman & Greenland, 2002; Stein et al., 2006;). Whether this 
difference is reflective of methodological issues or more substantial biological differences between 
TTM and OCD, however, remains unclear.
This study found no differences between those who did and did not respond to placebo. 
Contrary to our expectations, baseline symptom severity did not differ between placebo 
responders and non-responders. The differences between our results and studies of other mental 
health conditions such as major depressive disorder in which baseline symptom severity was a
meaningful predictor of placebo response (Stein et al., 2006; Nierenberg et al., 2015) could reflect 
the particular characteristics of our subject population or of the disorder itself. Surprisingly, in 
view of the contribution of placebo response to clinical outcomes in trials, relatively few studies 
have explored predictors of placebo response, especially so in obsessive-compulsive and related 
disorders. Our findings of a lack of predictive variables are in broad terms with several previous 
papers in OCD, which reported no statistically significant predictors (DeVeaugh-Geiss et al., 
1990; Mataix-Cols et al., 1999). 
Our comparison of baseline characteristics between placebo responders and active 
treatment responders (data pooled from the same source studies) was similarly negative, except 
for two findings. Active treatment responders stayed in the trials for a longer period of time and 
had marginally higher occurrence of OCD than placebo responders. The former result probably 
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stems from greater treatment benefit participants may experience with at least some of the active 
treatments reported in the literature, compared to placebo, even if placebo subjects respond 
somewhat to placebo. The latter result is likely a chance finding as the actual numbers of patients 
with OCD was low in both groups, and data were generally from randomized trials. 
One possible explanation for the high placebo response in TTM studies could be 
phenotypic variation seen in the disorder.  For example, some individuals pull only from their 
eyebrows or eyelashes. In these cases, it is quite common to pull all of the hair and then report no 
pulling for several weeks until the hair regrows. This is quite distinct from people who pull from 
their heads as that variation tends to be more chronic. Of course, a complication is that many 
people pull from several areas as well. Having said that, future studies may wish to enroll only 
those who pull from their heads and therefore have a chronic and predictable course so that 
change in behavior could more reliably be attributed to the intervention and not the lack of hair or 
need for hair to regrow.
This study suggests that few (if any) typically collected baseline clinical characteristics in 
TTM distinguish placebo responders from non-responders, but there exist several limitations to 
the studies included in the pooled analysis. Some studies unrelated to TTM suggest that 
expectancy (i.e. an individual’s beliefs about whether he or she will improve due to the treatment) 
may play a large role in a placebo response (Brown, 1994; Linden, 2017). Expectancy was not 
measured in the studies analyzed here. Although the MGH-HPS scoring has demonstrated strong 
validity and reliability in previous trials as reflecting a response to medication, the ideal threshold 
for response remains somewhat in doubt (Houghton et al., 2015). We chose a 35% reduction as 
being clinically meaningful, but some authors suggest that a 45% reduction may be more optimal 
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for TTM (Houghton et al., 2015). In response to this suggestion, we also examined the current 
measures using a 45% definition in a post-hoc analysis (data not reported), with similar lack of 
significant results. Some clinical measures were available only for a subset of individuals in the 
pooled dataset. This study did not examine baseline cognition or brain function. Such types of 
baseline measures would merit scrutiny in future work. This may in the future be a useful means 
of distinguishing placebo responders from non-responders before treatment, especially given that 
the placebo response can be linked with changes in brain functioning in other context (Leuchter et 
al., 2002). The studies included in the present paper had some restrictions on comorbidity in the 
protocols which might explain the low rates of comorbid OCD or alcohol use disorder.  If the 
studies had broader inclusion criteria allowing for comorbidity, it is possible that certain co-
occurring disorders may have contributed to the placebo response. The duration of treatment by 
week is reported and thus it would be important to analyze the placebo for each week of the 
studies. Given the collective data, this was not possible across all studies and should be noted as a 
limitation. Lastly, although this study represents the largest sample of subjects in treatment trials 
for TTM, the sample size is still relatively small and thus had only modest power to detect 
moderate effect size.  The current sample size, however, had adequate power (power ~ 0.80) to 
detect a group difference on a given measure of interest with medium (Cohen’s D at least 0.6) 
effect size, and it had very high power (power ~ 0.96) to detect a group difference with large 
effect size (Cohen’s D of 0.8). 
Placebo-controlled studies are the gold standard for the examination of pharmacological 
interventions. Individuals with TTM who respond to placebo appear no different clinically from 
those who do not respond to placebo, based on the types of measure typically collected in existing 
16
clinical trials. Given the fairly high estimated prevalence of TTM (Christensen et al., 1991; Odlaug 
& Grant, 2010) and the associated reduced quality of life in those who struggle with this disorder 
(Houghton et al. 2016; Odlaug et al. 2010; Tung et al., 2014), further exploration of placebo 
response will be crucial for developing better pharmacological interventions.  Of course, it is not 
possible to discuss meaningfully treatment resistance in TTM since there is no licensed treatment 
and only a limited evidence base of efficacy for any treatment. 
17
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3Abstract
Background: Trichotillomania is a functionally impairing, often overlooked disorder with no FDA-
approved medications indicated for its treatment. The ability of clinical trials to detect beneficial 
effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo 
response rate. Very little is known about baseline demographic and clinical characteristics that 
may be predictive of placebo response in such patients. 
Methods: 104 participants assigned to placebo were pooled from five double-blind trials
conducted at three sites in the United States and Canada. Participants were classified as placebo 
responders or non-responders based on a cut-off of 35% reduction in symptom severity on the 
Massachusetts General Hospital Hair Pulling Scale (MGH-HPS). Baseline group differences were 
characterized using t-tests and equivalent non-parametric tests as appropriate. 
Results: Thirty-one percent of individuals assigned to placebo treatment showed a significant 
clinical response to placebo.  Placebo responders (n=32) and non-responders (n=72) did not differ 
significantly on any demographic or clinical variable.
Discussion: Predictors of placebo response for trichotillomania remain elusive and do not appear 
similar to those reported for other mental health disorders. 
4Introduction
Trichotillomania (TTM) is a potentially disabling, under-recognized condition in which 
individuals repeatedly pull out their hair, leading to hair loss. Psychosocial problems are common 
among individuals with TTM and may include significantly reduced quality of life, lowered self-
esteem, and impaired social functioning (Diefenbach et al., 2005; Houghton et al., 2016; Grant 
and Chamberlain, 2016). Although trichotillomania has been described for almost two centuries, it
remains poorly understood with limited data regarding pathophysiology and treatment 
(Christenson & Mansueto, 1999; Chamberlain et al., 2009; Grant and Chamberlain, 2016). 
Most of the double-blind, placebo-controlled pharmacological studies of TTM have failed 
to separate symptomatic changes significantly from placebo. Interestingly, our clinical experience 
suggests that in many cases this lack of effectiveness seems less to do with the medication failing 
to produce results and more to do with the high placebo response rates. For example, in a double-
blind study of inositol, 37% of the placebo group (using a last observation carried forward 
approach; LOCF) responded (Leppink et al., 2016). Understanding the complexity of the placebo 
response in these disorders is challenging due to the limited sizes of the research samples (e.g., 
sample sizes of <25 taking placebo in any single study). The present study seeks to overcome this 
limitation by using a relatively large data set which combines participants from five double-blind, 
placebo controlled pharmacological trials in TTM conducted in the United States and Canada 
(Dougherty et al., 2006; Grant et al., 2009; Van Ameringen et al., 2010; Grant et al., 2014; 
Leppink et al., 2016).
Understanding the factors associated with a placebo response in TTM may allow for a
5more efficient examination of potentially beneficial pharmacological treatments for this disabling 
disorder. Here, we pooled data from studies in which all participants met diagnostic criteria for 
TTM, took placebo pills, and were seen regularly by a medical professional. Many factors have 
been suggested to contribute to high placebo response rates clinical trials in mental health. In the 
case of major depressive disorder, interpersonal interactions, the strength of the therapeutic 
alliance with research personnel (Leuchter et al., 2014), or lesser levels of depression severity 
(Khan et al., 2002; Khan et al., 2005) may result in a placebo response.  Data from trials of 
bipolar depression suggest that baseline illness severity and trial duration predict placebo response 
(Neirenberg et al., 2015). The case of obsessive compulsive disorder, however, has yielded no 
clear clinical variables associated with the placebo response (Mataix-Cols, et al., 1999). Based on 
the (admittedly limited) extant mental health literature and our clinical experience, we 
hypothesized that the placebo effect in TTM would be associated with milder illness severity at 
baseline.
Methods
Subjects
Data from participants in TTM treatment studies at the University of Chicago, University 
of Minnesota, McMaster University, and Massachusetts General Hospital (MGH)/Harvard 
Medical School who were assigned to placebo during the clinical trial were included in this study
(one exception was the sertraline trial which had a 2-week single-blind placebo phase prior to 
treatment assignment in the double-blind portion of the study and only 2 were randomized to 
placebo treatment in this study arm). All participants had a primary diagnosis of TTM based on 
6expert clinical assessment. As is customary in TTM research, prior to May 2013, the diagnosis 
was based on DSM-IV criteria with or without the endorsement of increasing and decreasing 
tension associated with pulling (criteria B and C). After the release of the DSM-5 in May 2013, all 
subjects met the DSM-5 criteria for TTM. Other inclusion criteria included age 18 or older, the 
ability to be interviewed in person, and able to provide written informed consent. Participants 
from MGH were excluded if they met criteria for a lifetime diagnosis of psychosis, autism, or 
mental retardation. Participants at the University of Chicago and the University of Minnesota 
were excluded if they were pregnant, met lifetime criteria for bipolar disorder or a psychotic 
disorder, or had an organic mental disorder.  Participants taking any psychotropic medications 
were included as long as the dose of medication had been stable for at least three months prior to 
study entry. Participants taking part at McMaster University were excluded if they had comorbid 
primary mental disorders; were less than moderately ill at baseline; had received olanzapine 
without success in the past; had comorbid OCD, depression, substance use disorder; or had a 
lifetime history of schizophrenia, bipolar disorder, dementia, or other neurologic disorders. 
All study procedures were carried out in accordance with the latest version of the 
Declaration of Helsinki. Study approvals were received from the Institutional Review Boards of 
all relevant institutions prior to study initiation. Detailed methodologies of the various clinical 
trials have been previously published (Dougherty et al., 2006; Grant et al., 2009; Van Ameringen 
et al., 2010; Grant et al., 2014; Leppink et al., 2016). Data were de-identified according to the 
Safe Harbor method for de-identification prior to data sharing (§164.514(b)) (U.S. Department of 
Health & Human Services, 2012). After all procedures were explained, all participants provided 
written informed consent.
7All participants in the trials completed a full psychiatric assessment using the Structured 
Clinical Interview for DSM-IV (SCID-I) (First et al. 1995). Subjects also completed general 
demographic questionnaires, and self-report and clinician-administered severity measures. In 
addition, each subject underwent a semi-structured interview to examine psychiatric disorders in 
first-degree relatives (except for the sertraline study). No relatives were interviewed directly.
Assessments
The Massachusetts General Hospital Hair Pulling Scale (MGH-HPS) (Keuthen et al., 
1995) was used to assess severity of TTM symptoms.: The MGH-HPS is a valid and reliable 
seven-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived 
control over behavior, and distress associated with hair pulling over the preceding seven days. 
Analysis of the MGH-HPS has demonstrated two separate factors with acceptable reliability for 
both: “severity” and “resistance and control” (Keuthen et al., 2007). 
Psychosocial functioning was assessed using the Sheehan Disability Scale (SDS) 
(Sheehan, 1983): The SDS is a valid and reliable, three-item, self-report scale that assesses 
psychosocial functioning in work, social or leisure activities, and home/family life. Scores on the 
scale range from 0 to 30 with higher scores indicating better perceived psychosocial functioning.
Depression and anxiety symptoms over the past month were assessed using clinician-
administered Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and Hamilton 
Anxiety Rating Scale (HAM-A; Hamilton, 1959), respectively. Scores on these two measures 
were not a basis for inclusion/exclusion.
8Data Analysis
Baseline characteristics of the placebo participants pooled from all of the studies were 
presented in terms of means and standard deviations for continuous variables and frequencies and 
percentages for categorical variables. 
Patients were grouped as placebo responders (>35% reduction in MGH-HPS total scores 
from baseline to end-point) or non-responders. The two groups were compared on pertinent 
demographic and clinical measures using independent sample t-tests or equivalent non-parametric 
tests as indicated in the text. This being an exploratory study, statistical significance was defined 
as p<0.05 uncorrected, one-tailed.
As a secondary analysis, we also pooled all data from the same studies from active 
treatment responders, and compared these data to those of placebo responders.
Results
Data from 104 participants with primary TTM (N=91 [87.5%] female, mean age 32.6 ±
11.0 years) who were assigned placebo were included in the analysis. In the pooled analysis, 
31.4% of participants assigned to placebo improved at least 35% on the MGH-HPS during 
placebo treatment. 
In terms of the individual studies, the sample sizes for those receiving placebo, and N [%] 
of subjects responding to placebo, were as follows: Inositol N=19, 7 [36.8%] were placebo 
responders; N-acetylcysteine (NAC) N=25, 6 [24.0%] were placebo responders; Naltrexone 
N=30, 9 [30.0%] were placebo responders; Olanzapine N=12, 3 [25.0%] were placebo 
responders; Sertraline N=18, 7 [39.9%] were placebo responders. The studies did not differ 
9significantly on placebo response rate (Likelihood Ratio = 1.619, df=4, p=0.805). 
Clinical variables of responders and non-responders are presented in Table 1, where it can 
be seen that the groups did not differ from each other in terms of demographic variables or clinical 
characteristics. Clinical variables of placebo responders are compared to reference data for active 
treatment responders in Table 2. Active treatment responders completed significantly more study 
weeks than placebo responders, and had marginally higher rate of OCD (although OCD was 
uncommon in both groups). 
Table 1. Clinical Variables of Participants with Trichotillomania Who Did and Did Not 
Respond to Placebo
Variables Those Who 
Responded to 
Placebo (n=32)
Those Who Did 
Not Respond to 
Placebo (n=72)
Statistical Test P 
value
Age, years 30.4 (10.9) 33.5 (11.0) t=1.314, df=1,102 0.192
Gender, female, N [%] 28 [87.5%] 63 [87.5%] LR=0.772, df=2 @ 0.680
Education level 3.6 (1.2) 3.6 (1.3) t=0.062, df=1,68 0.951
Race, white Caucasian, N [%] 20 [98.0%] 48 [98.0%] LR=0.691, df=1 0.406
Frequency of hair pulling
(mean number of minutes per 
day during the week prior to 
study entry)
66.6 (38.6) 87.7 (67.1) t=1.379, df=1,72 0.172
10
MGH-HPS total score at 
baseline
17.4 (3.4) 18.2 (4.6) t=0.881, df=1,102 0.380
Weeks of study completed 8.5 (3.6) 8.3 (3.9) t=-0.193, df =1,72 0.848
Previous treatment for 
trichotillomania, yes, N[%]
14 [63.6%] 29 [56.9%] LR = 0.294, df=1 0.588
First degree relative with 
grooming disorder, “yes” N[%]
3 [13.6%] 6 [11.5%] LR = 0.063, df=1 0.803
Sheehan Disability Scale 10.9 (6.7) 9.3 (6.3) t=0.928, df=1,102 0.357
HAM-A 4.2 (3.4) 4.7 (3.9) t=0.489, df=1,72 0.626
HAM-D 5.6 (5.9) 6.6 (6.9) t=0.633, df=1,102 0.509
Lifetime Psychiatric History
Mood Disorder
Anxiety Disorder
Alcohol Use Disorder
OCD
ADHD
14 [63.6%]
5 [22.7%]
1 [4.5%]
0 [0%]
1 [4.5%]
19 [36.5%]
9 [17.3%]
3 [5.8%]
2 [3.8%]
9 [17.3%]
LR = 0.0, df=1
LR = 0.288, df=1
LR = 0.047, df=1
LR=1.435, df=1
LR = 2.561, df=1
0.989
0.591
0.829
0.231
0.145
All values are mean (±SD) for continuous variables and N [%] for categorical variables. 
Abbreviations: LR = likelihood ratio test. @ = one individual in the non-placebo 
responders group identified as intersex. 
Table 2. Clinical Variables of Participants with Trichotillomania Who Were Placebo 
Responders Compared to Active Treatment Responders
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Variables Those Who 
Responded to 
Placebo (n=32)
Those Who 
Responded to 
Active 
Treatment 
(n=52)
Statistical Test P 
value
Age, years 30.4 (10.9)
32.6 (11.1)
t=0.865, df=1,82 0.390
Gender, female, N [%] 28 [87.5%]
44 [84.6%]
LR=0.992, df=2 @ 0.601
Education level 3.6 (1.2)
3.8 (1.0) t=0.638, df=1,55 0.527
Race, white Caucasian, N [%] 20 [98.0%] 33 [94.3%] LR=1.851, df=1 0.396
Frequency of hair pulling
(mean number of minutes per 
day during the week prior to 
study entry)
66.6 (38.6) t=1.379, df=72 0.172
MGH-HPS total score at 
baseline
17.4 (3.4) 17.9 (4.1) t=0.619, df=1,82 0.538
Weeks of study completed 8.5 (3.6) 10.2 (2.2) t=2.073, df=1,56 0.047
Previous treatment for 
trichotillomania, yes, N[%]
14 [63.6%] 20 [55.6%] LR=0.370, df = 1 0.543
First degree relative with 
grooming disorder, “yes” N[%]
3 [13.6%] 6 [16.7%] LR = 0.097, df=1 0.755
Sheehan Disability Scale 10.9 (6.7) 11.4 (7.0) t=1.145, df=1,56 0.258
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HAM-A 4.2 (3.4) 4.2 (0.5) t=0.044, df=1,56 0.965
HAM-D 5.6 (5.9) 6.0 (8.1) t=1.323, df=1,80 0.190
Lifetime Psychiatric History
Mood Disorder
Anxiety Disorder
Alcohol Use Disorder
OCD
ADHD
14 [63.6%]
5 [22.7%]
1 [4.5%]
0 [0%]
1 [4.5%]
16 [44.4]
9 [25.0%]
0 [0.0%]
4 [11.1%]
5 [13.9%]
LR=0.370, df=1
LR=0.039, df=1
LR=1.968, df=1
LR=3.995, df=1
LR=1.433 , df=1
0.543
0.844
0.161
0.046
0.231
All values are mean (±SD) for continuous variables and N [%] for categorical variables. 
Abbreviations: LR = likelihood ratio test. @  = one individual in the non-placebo 
responders group identified as intersex. 
Discussion
To our knowledge, this is the first study that has examined clinical variables associated 
with the placebo response in the pharmacological treatment of TTM. Given that the pooled 
placebo response in these studies was 31%, and that there is as of yet no FDA-approved 
medication indicated for the treatment of TTM, determining predictors of placebo response is
crucial for the timely and cost-effective development of pharmacological interventions.
Knowledge of variables associated with placebo response might also be useful for sample 
enrichment in clinical trials.  In addition, a placebo response rate of 31% suggests that larger 
numbers will be needed in future placebo controlled efficacy studies of TTM than have been 
previously considered necessary.
Some research suggests that the placebo effect in clinical drug trials generally may 
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influence as many as 49% of treated patients, that the effect may be related to symptom severity, 
and that its duration may vary from minutes to years (Breidert & Hofbauer, 2009). Interestingly, 
the placebo response rate in our sample is much higher than previously found in OCD treatment 
trials, a disorder with possible biological links to TTM (<20%; Greist et al., 1995; Stein et al., 
1995; Pigott & Seay, 1999; Ackerman & Greenland, 2002; Stein et al., 2006;). Whether this 
difference is reflective of methodological issues or more substantial biological differences between 
TTM and OCD, however, remains unclear.
This study found no differences between those who did and did not respond to placebo. 
Contrary to our expectations, baseline symptom severity did not differ between placebo 
responders and non-responders. The differences between our results and studies of other mental 
health conditions such as major depressive disorder in which baseline symptom severity was a
meaningful predictor of placebo response (Stein et al., 2006; Nierenberg et al., 2015) could reflect 
the particular characteristics of our subject population or of the disorder itself. Surprisingly, in 
view of the contribution of placebo response to clinical outcomes in trials, relatively few studies 
have explored predictors of placebo response, especially so in obsessive-compulsive and related 
disorders. Our findings of a lack of predictive variables are in broad terms with several previous 
papers in OCD, which reported no statistically significant predictors (DeVeaugh-Geiss et al., 
1990; Mataix-Cols et al., 1999). 
Our comparison of baseline characteristics between placebo responders and active 
treatment responders (data pooled from the same source studies) was similarly negative, except 
for two findings. Active treatment responders stayed in the trials for a longer period of time and 
had marginally higher occurrence of OCD than placebo responders. The former result probably 
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stems from greater treatment benefit participants may experience with at least some of the active 
treatments reported in the literature, compared to placebo, even if placebo subjects respond 
somewhat to placebo. The latter result is likely a chance finding as the actual numbers of patients 
with OCD was low in both groups, and data were generally from randomized trials. 
One possible explanation for the high placebo response in TTM studies could be 
phenotypic variation seen in the disorder.  For example, some individuals pull only from their 
eyebrows or eyelashes. In these cases, it is quite common to pull all of the hair and then report no 
pulling for several weeks until the hair regrows. This is quite distinct from people who pull from 
their heads as that variation tends to be more chronic. Of course, a complication is that many 
people pull from several areas as well. Having said that, future studies may wish to enroll only 
those who pull from their heads and therefore have a chronic and predictable course so that 
change in behavior could more reliably be attributed to the intervention and not the lack of hair or 
need for hair to regrow.
This study suggests that few (if any) typically collected baseline clinical characteristics in 
TTM distinguish placebo responders from non-responders, but there exist several limitations to 
the studies included in the pooled analysis. Some studies unrelated to TTM suggest that 
expectancy (i.e. an individual’s beliefs about whether he or she will improve due to the treatment) 
may play a large role in a placebo response (Brown, 1994; Linden, 2017). Expectancy was not 
measured in the studies analyzed here. Although the MGH-HPS scoring has demonstrated strong 
validity and reliability in previous trials as reflecting a response to medication, the ideal threshold 
for response remains somewhat in doubt (Houghton et al., 2015). We chose a 35% reduction as 
being clinically meaningful, but some authors suggest that a 45% reduction may be more optimal 
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for TTM (Houghton et al., 2015). In response to this suggestion, we also examined the current 
measures using a 45% definition in a post-hoc analysis (data not reported), with similar lack of 
significant results. Some clinical measures were available only for a subset of individuals in the 
pooled dataset. This study did not examine baseline cognition or brain function. Such types of 
baseline measures would merit scrutiny in future work. This may in the future be a useful means 
of distinguishing placebo responders from non-responders before treatment, especially given that 
the placebo response can be linked with changes in brain functioning in other context (Leuchter et 
al., 2002). The studies included in the present paper had some restrictions on comorbidity in the 
protocols which might explain the low rates of comorbid OCD or alcohol use disorder.  If the 
studies had broader inclusion criteria allowing for comorbidity, it is possible that certain co-
occurring disorders may have contributed to the placebo response. The duration of treatment by 
week is reported and thus it would be important to analyze the placebo for each week of the 
studies. Given the collective data, this was not possible across all studies and should be noted as a 
limitation. Lastly, although this study represents the largest sample of subjects in treatment trials 
for TTM, the sample size is still relatively small and thus had only modest power to detect 
moderate effect size.  The current sample size, however, had adequate power (power ~ 0.80) to 
detect a group difference on a given measure of interest with medium (Cohen’s D at least 0.6) 
effect size, and it had very high power (power ~ 0.96) to detect a group difference with large 
effect size (Cohen’s D of 0.8). 
Placebo-controlled studies are the gold standard for the examination of pharmacological 
interventions. Individuals with TTM who respond to placebo appear no different clinically from 
those who do not respond to placebo, based on the types of measure typically collected in existing 
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clinical trials. Given the fairly high estimated prevalence of TTM (Christensen et al., 1991; Odlaug 
& Grant, 2010) and the associated reduced quality of life in those who struggle with this disorder 
(Houghton et al. 2016; Odlaug et al. 2010; Tung et al., 2014), further exploration of placebo 
response will be crucial for developing better pharmacological interventions.  Of course, it is not 
possible to discuss meaningfully treatment resistance in TTM since there is no licensed treatment 
and only a limited evidence base of efficacy for any treatment. 
17
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